Quick Answer
ACADIA PHARMACEUTICALS INC reported Cash and Equivalents of $177.69 million for fiscal year 2025.
ACADIA PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $177.69M | -44.4% |
| 2024 | $319.59M | +69.4% |
| 2023 | $188.66M | +64.3% |
| 2022 | $114.85M | -22.1% |
| 2021 | $147.44M | -54.8% |
| 2020 | $326.03M | +71.9% |
| 2019 | $189.68M | +40.8% |
| 2018 | $134.76M | +94.1% |
| 2017 | $69.42M | -57.6% |
| 2016 | $163.62M | +60.2% |
| 2015 | $102.14M | +65.1% |
| 2014 | $61.85M | +428.4% |
| 2013 | $11.71M | -79.8% |
| 2012 | $57.90M | +740.5% |
| 2011 | $6.89M | +0.6% |
| 2010 | $6.85M | -62.2% |
| 2009 | $18.12M | -14.4% |
| 2008 | $21.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $258.00M | +66.3% | +1.7% |
| June 30, 2025 | $253.64M | +43.2% | +16.5% |
| March 31, 2025 | $217.70M | +6.3% | -31.9% |
| December 31, 2024 | $319.59M | +69.4% | +106.0% |
| September 30, 2024 | $155.15M | +58.0% | -12.4% |
| June 30, 2024 | $177.13M | +64.1% | -13.5% |
| March 31, 2024 | $204.75M | -29.6% | +8.5% |
| December 31, 2023 | $188.66M | +64.3% | +92.1% |
- ACADIA PHARMACEUTICALS INC showed a decrease of -44.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, ACADIA PHARMACEUTICALS INC’s cash and equivalents has grown by 739.3% (from $21.17 million to $177.69 million).
- The most recent figure is from ACADIA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: